6/28/23, 12:17 AM CORP Pathway Feedback Search Clinical Topics Home Studies CORP CORP Disease Acute pericarditis Trial question What is the role of colchicine in patients with a first recurrence of pericarditis? Study design Multi-center Double blinded RCT Population Characteristics of study participants 47.5% female N = 120 52.5% male 120 patients (57 female, 63 male) Inclusion criteria: patients with a first recurrence of pericarditis Key exclusion criteria: pericarditis with tuberculous, purulent, or neoplastic causes; known severe liver disease; known myopathy; known blood dyscrasias; gastrointestinal disease; or known hypersensitivity to colchicine Interventions N=60 colchicine (1.0-2.0 mg on the first day followed by a maintenance dose of 0.5-1.0 mg/d for 6 months in addition to conventional treatment) N=60 placebo (matching placebo daily for 6 months in addition to conventional treatment) Primary outcome Recurrence at 18 months 55.0 % 55 https://web.pathway.md/studies/recTXMA4agLsJOvNZ 1/2 6/28/23, 12:17 AM CORP Pathway 41.3 % 27.5 % 24 Significant decrease 13.8 % NNT = 3 0.0 % Colchicine Placebo Significant decrease in recurrence at 18 months (24% vs. 55%; RR 0.44, 95% CI 0.27 to 0.73) Secondary outcomes Significant decrease in persistence of symptoms at 72 hours (23% vs. 53%; RR 0.43, 95% CI 0.26 to 0.63) Significant increase in remission at 1 week (82% vs. 48%; RR 1.71, 95% CI 0.7 to 2.72) Significant increase in time to recurrence (2.5 vs. 1; MD 1.5, 90% CI 0 to 19.1) Safety outcomes No significant differences in side effects (7% vs. 7%, p > 0.99) and drug withdrawal (8% vs. 5%, p=0.89). Conclusion In patients with a first recurrence of pericarditis, colchicine was superior to placebo with respect to recurrence at 18 months. Reference Imazio M, Brucato A, Cemin R et al. Colchicine for recurrent pericarditis (CORP): a randomized trial. Ann Intern Med. 2011 Oct 4;155(7):409-14. Open reference URL https://web.pathway.md/studies/recTXMA4agLsJOvNZ 2/2